Treatment of opioid-induced constipation: Focus on the peripheral μ-opioid receptor antagonist methylnaltrexone

Drugs

Volumn 73, Issue 12, 2013, Pages 1297-1306

  Rauck, Richard L ^a  

^a Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BISACODYL; CHLORIDE CHANNEL STIMULATING AGENT; CISAPRIDE; DOCUSATE SODIUM; ISPAGULA; LACTULOSE; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM HYDROXIDE; MU OPIATE RECEPTOR ANTAGONIST; OPIATE; PLACEBO; POLYCARBOPHIL CALCIUM; PRUCALOPRIDE; SENNOSIDE; SORBITOL; TEGASEROD;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADVERSE DRUG REACTION; ANALGESIA; ANALGESIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER PAIN; CANCER PATIENT; CARDIOVASCULAR RISK; COMPASSIONATE USE; CONGESTIVE HEART FAILURE; CONSTIPATION; CRITICALLY ILL PATIENT; DIARRHEA; DIETARY FIBER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES IMPACTION; FLATULENCE; FLUID INTAKE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; HEALTH CARE COST; HEART INFARCTION; HOSPICE; HUMAN; HYPERHIDROSIS; IN VITRO STUDY; INTESTINE EPITHELIUM; INTESTINE FLUID; INTESTINE MUSCLE; KIDNEY FAILURE; LONG TERM CARE; META ANALYSIS; NAUSEA; NURSING HOME; OBSERVATIONAL STUDY; OPEN STUDY; OPIOID INDUCED CONSTIPATION; PALLIATIVE THERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; POSTOPERATIVE ILEUS; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SMALL INTESTINE RESECTION; ST SEGMENT DEPRESSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DIETARY FIBER; HUMANS; LAXATIVES; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, OPIOID, MU;

EID: 84883227562     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0084-5     Document Type: Review

References (70)

1. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S1-4.
2. McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11(3 Suppl):3-9.
3. Hsieh C. Treatment of constipation in older adults. Am Fam Physician. 2005;72(11):2277-84.
4. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91.
5. Schumacher MA, Basbaum AI, Way WL. Opioid analgesics and antagonists. In: Katzung BG, editor. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical; 2009. p. 531-52.
6. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1-3):11-7.
7. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996;59(4):469-75.
8. Manara L, Bianchi G, Ferretti P, et al. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol Exp Ther. 1986;237(3):945-9.
9. Tavani A, Bianchi G, Ferretti P, et al. Morphine is most effective on gastrointestinal propulsion in rats by intraperitoneal route: evidence for local action. Life Sci. 1980;27(23):2211-7.
10. Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther. 2010;27(10):714-30.
11. Chou R, Fanciullo GJ, Fine PG, American Pain Society; American Academy of Pain Medicine Opioid Guidelines Panel, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-30.
12. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-65.
13. Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224-32.
14. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med. 1998;12(5):375-82.
15. Candrilli SD, Davis KL, Iyer S. Impact of constipation on opioid use patterns, health care resource utilization, and costs in cancer patients on opioid therapy. J Pain Palliat Care Pharmacother. 2009;23(3):231-41.
16. Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manage Care. 2010;19(3):44-51.
17. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manage. 2009;5(3):137-44.
18. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35-42.
19. Penning-van Beest FJ, van den Haak P, Klok RM, et al. Quality of life in relation to constipation among opioid users. J Med Econ. 2010;13(1):129-35.
20. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835-42.
21. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181-7.
22. Ternent CA, Bastawrous AL, Morin NA, et al. Practice parameters for the evaluation and management of constipation. Dis Colon Rectum. 2007;50(12):2013-22.
23. Walters JB, Montagnini M. Current concepts in the management of opioid-induced constipation. J Opioid Manage. 2010;6(6):435-44.
24. Brandt LJ, Prather CM, Quigley EM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100(Suppl 1):S5-21.
25. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 - guidance. Pain Physician. 2012;15(Suppl 3):S67-116.
26. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58-68.
27. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;(1):CD003448.
28. Thomas JR, Cooney GA, Slatkin NE. Palliative care and pain: new strategies for managing opioid bowel dysfunction. J Palliat Med. 2008;11(Suppl 1):S1-19.
29. Tack J. Current and future therapies for chronic constipation. Best Pract Res Clin Gastroenterol. 2011;25(1):151-8.
30. Bader S, Jaroslawski K, Blum HE, et al. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201-11.
31. Emmanuel A. Current management strategies and therapeutic targets in chronic constipation. Ther Adv Gastroenterol. 2011;4(1):37-48.
32. Amitiza (lubiprostone) capsules [package insert]. Deerfield: Takeda Pharmaceuticals America, Inc.; 2013.
33. Entereg (alvimopan) capsules [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc., 2012.
34. Relistor (methylnaltrexone bromide) subcutaneous injection [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc.; 2012.
35. van der Spoel JI, Oudemans-van Straaten HM, Kuiper MA, et al. Laxation of critically ill patients with lactulose or polyethylene glycol: a two-center randomized, double-blind, placebo-controlled trial. Crit Care Med. 2007;35(12):2726-31.
36. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004;(3):CD004847.
37. Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494-503.
38. Fallon M, O'Neill B. ABC of palliative care. Constipation and diarrhoea. BMJ. 1997;315(7118):1293-6.
39. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10(2):135-44.
40. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23(1):48-53.
41. 3H]alvimopan binding to the μ opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol. 2005;520:29-36.
42. Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047-56.
43. A study of S-297995 for the treatment of opioid-induced constipation in subjects with non-malignant chronic pain receiving opioid therapy [ClinicalTrials.gov identifier NCT01443403]. 2012 Nov 27 [online]. Bethesda: US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ ct2/show/NCT01443403. (Accessed 1 Feb 2013).
44. Paulson D, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment-randomized clinical trial. J Pain. 2005;6(3):184-92.
45. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428-40.
46. Jansen J-P, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):185-93.
47. Irving G, Pénzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175-84.
48. Bream-Rouwenhorst HR, Cantrell MA. Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009;66(14):1267-77.
49. Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010;170(22):1968- 78.
50. Carman WJ, Su S, Coo SF, et al. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. Pharmacoepidemiol Drug Saf. 2011;20:754-62.
51. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39-46.
52. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-43.
53. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38(5):683-90.
54. Slatkin NE, Lynn R, Su C, et al. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011;42(5):754-60.
55. Corken Mackey A, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage. 2010;40(1):e1-3.
56. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554-62.
57. Michna E, Weil AJ, Duerden M, et al. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med. 2011;12(8):1223-30.
58. Blonsky E, Watier A, Schulman S, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic non-malignant pain: open-label results [abstract no. 149]. Reg Anesth Pain Med. 2009;34(5):98.
59. Webster L, Michna E, Khan A, et al. The long-term efficacy of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain [abstract no. 376]. J Pain. 2011;12(Suppl 4):P70.
60. Webster L, Michna E, Khan A, et al. The long-term safety of subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic nonmalignant pain [abstract no. 378]. J Pain. 2011;12(Suppl 4):P70.
61. Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67-72.
62. Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebo- controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain [abstract no. 906]. Gastroenterology. 2010;138(5 Suppl 1):S129.
63. Jamal MM, Mareya SM, Woldegeorgis F, et al. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial [poster no. 848a]. Digestive Diseases Week 2012, San Diego; May 19-22, 2012.
64. Spierings E, Joswick T, Lindner E, et al. Long-term safety and efficacy of lubiprostone in opioid-induced bowel dysfunction in patients with chronic, non-cancer pain: results of a phase 3, open-label clinical trial [abstract no. 322]. Am J Gastroenterol. 2012;107(Suppl 1):S138.
65. Mohammad S, Zhou Z, Gong Q, et al. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997;273(5 Pt 2):H2534-8.
66. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology. 2007;132(7):2287-90.
67. Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35(7):745-67.
68. Zelnorm (tegaserod maleate) information. 2012 May 11 [online]. Silver Spring, MD: US Department of Health and Human Services, US Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm103223.htm (Accessed 1 Feb 2013).
69. Sloots CEJ, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912-21.
70. Quigley EMM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012;5(1):23-30.